Core Points - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of selected units for the innovative task of biomedical materials, with a total of 86 units selected across 35 categories [2] - Five companies from Shandong have been selected, including Weihai Weigao Blood Collection Consumables Co., Ltd., Qingdao Haier Biomedical Co., Ltd., Shandong Guyu Spring Biotechnology Co., Ltd., Shandong Weigao Group Medical Polymer Products Co., Ltd., and Shandong Guocer Functional Materials Co., Ltd. [2] - The selected companies are focusing on various innovative materials such as polyethylene terephthalate, non-phthalate plasticizers, polyester-polyethylene glycol copolymers, high-end polypropylene, and 3D printing zirconia ceramic ink [2] Industry Support - Local industrial and information authorities will collaborate with drug supervision departments to enhance tracking and support for the selected units and projects [2] - There will be prioritized allocation of resources such as project land, energy, and pollution discharge indicators for the selected units [2] - After completing the innovation tasks within three years, the Ministry of Industry and Information Technology and the National Medical Products Administration will commission professional institutions to evaluate and select the outstanding units, with a limit of two winners per product [2]

Major Events - Xiaoma Zhixing-W (02026) has set the share price for its offering at HKD 139 [1] - Boleton (01333) has entered into a strategic cooperation with Fujian Rixin, focusing on autonomous driving for mining transportation [1] - Zhaojin Mining (01818) has signed a strategic cooperation memorandum with Ant Group [1] - Yimai Sunshine (02522) subsidiary has signed a data co-construction cooperation agreement with Beijing Xianxing District and Beijing Computing Power [1] - Yaojie Ankang-B (02617) has reached a project cooperation agreement with Neurocrine [1] - Heng Rui Pharmaceutical (01276) plans to include HRS-5965 capsules in the priority review process [1] Financial Data - XPeng Motors-W (09868) delivered 42,013 smart electric vehicles in October, a year-on-year increase of 76%, setting a new monthly delivery record [1] - Fuwai Group (01828) reported a sales revenue of USD 1.935 billion for the first three quarters, a year-on-year increase of 37% [1] - Shenzhen Holdings (00604) recorded total contract sales of approximately CNY 9.838 billion for the first three quarters, a year-on-year increase of 24% [1] - Weigao Group (01066) reported third-quarter revenue of approximately CNY 3.26 billion, a year-on-year growth of about 2.6% [1]

Core Viewpoint - Weigao Group (01066) announced a share repurchase of 300,400 shares scheduled for November 3, 2025 [1] Summary by Category Company Actions - Weigao Group plans to repurchase a total of 300,400 shares [1]

威高股份(01066)公布，2025年11月3日回购30.04万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月3日 (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 第一章節註釋： 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 山東威高集團醫用高分子製品股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01066 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,522,332,324 | RMB | | 0.1 | RMB | | 452,233,232.4 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 4,522,332,324 | RMB | | 0.1 | RMB | | 452, ...

Core Viewpoint - Weigao Group (01066) reported an unaudited revenue of approximately RMB 3.26 billion for the three months ending September 30, 2025, representing a year-on-year growth of about 2.6% [1] Revenue Breakdown - The orthopedic, interventional, and blood management segments experienced rapid revenue growth [1] - The pharmaceutical packaging and general medical device segments faced pressure on sales prices due to policy impacts, which negatively affected the overall revenue growth of the group [1]

格隆汇11月3日丨威高股份(01066.HK)公布，截至2025年9月30日止3个月，公司录得未经审核的收入约 人民币32.6亿元，较去年同期增长约2.6%。其中，骨科、介入、血液管理等分部取得较快收入增长；而 药品包装和通用医疗器械分部，由于冲管注射器等产品的销售价格受政策影响持续承压，对集团整体销 售收入增长有所拖累。 相关事件 威高股份(01066.HK)第三单季度未经审核收入32.6亿元 同比增长约2.6% 威高股份(01066.HK)拟将威高 普瑞注入威高血净 交易完成后或并表 ...

山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 自願性公告 第三季度最新營運表現 通用醫療器械 低個位數下降 藥品包裝 低個位數上升 介入 超過10%上升 本公告乃由山東威高集團醫用高分子製品股份有限公司（「本公司」，連同其附 屬公司統稱「本集團」）董事會（「董事會」）自願發出，以提供本集團近期之營運 表現。 截至2025年9月30日止3個月，本公司錄得未經審核之收入約人民幣32.6億元， 較去年同期增長約2.6%。其中，骨科、介入、血液管理等分部取得較快收入增 長；而藥品包裝和通用醫療器械分部，由於沖管注射器等產品的銷售價格受 政策影響持續承壓，對集團整體銷售收入增長有所拖累。 * 僅供識別 1 以下為各經營分部的收入較去年同期 ...

Core Viewpoint - The company plans to issue shares to acquire 100% equity of Weigao Puri from Weigao Co., Weihai Shengxi, and Weihai Ruiming, which is expected to constitute a major asset restructuring for the listed company [2] Group 1: Transaction Details - The transaction will add new business lines in the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems [2] - Following the completion of the transaction, the company aims to integrate the target company's technological accumulation and product layout to expand its product line into the pharmaceutical packaging sector [2] Group 2: Strategic Benefits - The company plans to leverage its own hollow fiber filtration technology advantages alongside the target company's rich customer resources in the biopharmaceutical sector [2] - This collaboration is expected to enable mutual empowerment in product technology reserves and sales channels for biopharmaceutical filter business, focusing on the upstream market of biopharmaceuticals [2]